Efficacy and safety of alemtuzumab in multiple sclerosis and impact on nursing role.
Alemtuzumab, a humanized monoclonal antibody, has shown efficacy for relapsing-remitting multiple sclerosis (MS) in phase 2 and phase 3 trials. Compared with subcutaneous interferon beta-1a, alemtuzumab significantly reduced the risk for accumulation of disability and the rate of relapse, and improved mean disability level from baseline. Notable safety and tolerability concerns include infusion-associated reactions, infections of predominantly mild-to-moderate severity, and autoimmune adverse events, principally thyroid disorders and immune thrombocytopenia. As emerging therapies such as alemtuzumab are approved for the treatment of MS, nurses specializing in the care of MS patients will make increasingly significant contributions to the education of patients, caregivers, and other health-care providers about these therapies' efficacy, tolerability, safety, and administration. This article reviews the phase 2 and phase 3 efficacy and safety results for alemtuzumab, with an emphasis on the role of nurses in communication about this treatment option for those with MS.
Department of Neurology, Wayne State University School of Medicine, Detroit, MI, USA (CC); Consultants in Neurology, Northbrook, IL, USA (CM); MS Clinic of Central Texas, Round Rock, TX, USA (LM); and ReSearch Pharmaceutical Services, Inc (RPS), Fort Washington, PA, USA (MSS).
Christina
C
Caon
Department of Neurology, Wayne State University School of Medicine, Detroit, MI, USA (CC); Consultants in Neurology, Northbrook, IL, USA (CM); MS Clinic of Central Texas, Round Rock, TX, USA (LM); and ReSearch Pharmaceutical Services, Inc (RPS), Fort Washington, PA, USA (MSS).
Cathy
C
Meyer
Department of Neurology, Wayne State University School of Medicine, Detroit, MI, USA (CC); Consultants in Neurology, Northbrook, IL, USA (CM); MS Clinic of Central Texas, Round Rock, TX, USA (LM); and ReSearch Pharmaceutical Services, Inc (RPS), Fort Washington, PA, USA (MSS).
Lori
L
Mayer
Department of Neurology, Wayne State University School of Medicine, Detroit, MI, USA (CC); Consultants in Neurology, Northbrook, IL, USA (CM); MS Clinic of Central Texas, Round Rock, TX, USA (LM); and ReSearch Pharmaceutical Services, Inc (RPS), Fort Washington, PA, USA (MSS).
M Shelton
MS
Smith